Childhood Cancer Data Initiative (CCDI): CCDI Pediatric In Vivo Testing Program - Leukemia

The goal of this study is to molecularly characterize a large panel of pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts (PDXs) previously established in immune-deficient mice. These PDXs are utilized as part of the NCI-funded Pediatric Preclinical In vivo Testing (PIVOT) program to identify novel agents and combinations. Biospecimen data include next-generation sequencing (RNAseq, whole exome sequencing, DNA copy number variation), whole-genome analysis of cytogenetic abnormalities, and DNA fingerprint for quality control.

• Study Weblinks:
  • Pediatric Preclinical In Vivo Testing consortium (PIVOT)
• Study Design:
  • Xenograft
• Study Type:
  • Copy Number Variation (CNV)
  • Exome Sequencing
  • Repository
  • RNA Sequencing
  • Xenograft
• Total number of consented subjects: 40
• Subject Sample Telemetry Report (SSTR)

Pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts (PDXs) established in immune-deficient (NOD/SCID or NSG) mice without prior ex vivo co-culture are included.

No exclusion criteria.

PDXs have been established since 2002.

• Primary Phenotype: Pediatrics
• Neoplasms
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Leukemia, Biphenotypic, Acute
• Heterografts

• Principal Investigator
  • Richard B. Lock, PhD. Children's Cancer Institute, UNSW Sydney, Sydney, NSW, Australia.
• Program Officer
  • Kathryn Evans, B Biomed Sci (Hons). Children's Cancer Institute, UNSW Sydney, Sydney, NSW, Australia.
• Bioinformatics Senior Scientist
  • Chelsea Mayoh, BSc. Children's Cancer Institute, UNSW Sydney, Sydney, NSW, Australia.
• Funding Sources
  • NCI CA199000. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • NHMRC APP1157871. NHMRC, Canberra, ACT, Australia.